Core Viewpoint - The company, Woge Optoelectronics, has addressed investor concerns regarding its business segments, including CPI aerospace applications, microfluidic biochips, and glass-based technologies, emphasizing its current production capabilities and market status. Group 1: CPI Products - The company has developed CPI (transparent polyimide) products for aerospace applications, but these have not yet achieved mass production, with current applications limited to a single satellite's flexible solar wing, resulting in a small order value [1] - Orders related to CPI products are still in the testing phase and are expected to contribute less than 0.1% to the company's revenue in 2025, indicating significant uncertainty regarding future order cycles and scale [1][2] - The company claims to be one of the few in China with a complete CPI production chain, but the commercial aerospace business is still in its early stages, primarily focused on R&D and small-scale production [2] Group 2: Microfluidic Biochips - The company is advancing the development and industrialization of microfluidic biochips, leveraging its expertise in glass-based precision processing, with products nearing mass production after successful customer sample validation [3] - The microfluidic biochip business primarily provides glass substrates or structural components for downstream clients, without involvement in chip design or manufacturing, and is currently focused on applications in in vitro diagnostics [3] - Expected sales revenue from microfluidic products in the biomedical sector for 2025 is projected to be $10.79 million, representing a very small proportion of the company's overall revenue, with no confirmed timeline for entering formal mass production [3]